Clinical Trends for September 2015

Ryan Syrek


September 25, 2015

Clinical Trend of the Week (Aug 29-Sept 4): Tardive Dyskinesia

Any time a new drug progresses in its research path, physicians take note. Last week, Neurocrine Biosciences Inc. announced that it completed subject randomization on its phase III clinical trial of a compound designed for use in patients with tardive dyskinesia. The compound, NBI-98854, is a vesicular monoamine transporter 2 and could potentially be the first treatment specifically approved for tardive dyskinesia, the symptoms of which are rarely reversible.

For more in-depth clinical information, see Tardive Dyskinesia.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: